ATS Journals | American Journal of Respiratory and Critical Care Medicine

Blood eosinophils and chronic obstructive pulmonary disease: a GOLD Science Committee 2022 review

Journal:	*American Journal of Respiratory and Critical Care Medicine*
Manuscript ID	Blue-202201-0209PP.R1
Manuscript Type:	PP - Pulmonary Perspective
Date Submitted by the Author:	28-Mar-2022
Complete List of Authors:	Singh, Dave; The University of Manchester Agusti, Alvar; Fundacio Clinic per a la Recerca Biomedica, Martinez, Fernando J.; Cornell Medical College, Papi, Alberto; University of Ferrara, Research Centre on Asthma and COPD Pavord, Ian; Oxford University, Nuffield department of Medicine, Respiratory Medicine Wedzicha, Jadwiga; Imperial College London, National Heart and Lung Institute Vogelmeier, Claus; University of Marburg, Pulmonary Diseases Halpin, David; University of Exeter College of Medicine, University of Exeter Medical School; Royal Devon and Exeter Hospital,
Subject Category:	9.03 COPD: Clinical Phenotypes < LUNG DISEASES, 9.14 COPD: Pharmacological Treatment < LUNG DISEASES
Keywords:	COPD, eosinophils, BIOMARKER, MICROBIOME, TYPE 2 INFLAMMATION

Monday, 28 March 2022

Blood eosinophils and chronic obstructive pulmonary disease: a GOLD Science Committee 2022 review

Dave Singh[1], Alvar Agusti [2], Fernando J. Martinez[3], Alberto Papi[4], Ian D Pavord [5], Jadwiga A Wedzicha[6], Claus F. Vogelmeier[7], David MG Halpin[8]

Affiliations

1. University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK
2. Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Spain
3. Weill Cornell Medicine, NY Presbyterian Hospital, New York, NY, USA
4. Respiratory Medicine Unit, University of Ferrara, University Hospital S.Anna, Ferrara, Italy
5. Oxford Respiratory NIHR BRC and Nuffield Department of Medicine, University of Oxford.
6. National Heart and Lung Institute, Imperial College, London, UK
7. Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany
8. University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK

Abstract word count: 233

Text body word count: 4320

Author's contributions: All authors discussed and agreed the manuscript content. DS and DH prepared first version of manuscript. All authors reviewed and edited the paper, and approved the final version.

Keywords: COPD, eosinophils, biomarker, microbiome, type 2 inflammation

Running head: GOLD 2022: Blood eosinophils and COPD

Abstract

COPD is a heterogeneous condition. Some patients benefit from treatment with inhaled corticosteroids (ICS) but this requires a precision medicine approach, based on clinical characteristics (phenotyping) and biological information (endotyping) in order to select patients most likely to benefit. The GOLD 2019 report recommended using exacerbation history combined with blood eosinophil counts (BEC) to identify such patients. Importantly, the relationship between BEC and ICS effects is continuous; no / small effects are observed at lower BEC, with increasing effects at higher BEC.

The GOLD 2022 report has added additional evidence and recommendations concerning the use of BEC in COPD in clinical practice. Notably, associations have been demonstrated in COPD patients between higher BEC and increased levels of type-2 inflammation in the lungs. These differences in type-2 inflammation can explain the differential ICS response according to BEC. Additionally, lower BEC are associated with greater presence of proteobacteria, notably haemophilus, and increased bacterial infections and pneumonia risk. These observations support management strategies that use BEC to help identify subgroups with increased ICS response (higher BEC) or increased risk of bacterial infection (lower BEC). Recent studies in younger individuals without COPD have also shown that higher BEC are associated with increased risk of FEV_1 decline and the development of COPD.

Here we discuss and summarise the GOLD 2022 recommendations concerning the use of BEC as a biomarker that can facilitate a personalised management approach in COPD.

Introduction

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in 2001 (1). Since then, GOLD has updated it yearly (2), the last time in 2022 (www.goldcopd.org). To do so, GOLD evaluates critically the new evidence since the previous publication and decides whether it merits (or not) inclusion in the most recent update. GOLD publishes specific recommendations and, sometimes, the main arguments behind them, but it often lacks space for a detailed discussion regarding the pros and cons behind each recommendation. To address this limitation, the Scientific Committee of GOLD decided to publish, separately from the main annual update, a series of papers that review and discuss topics of particular, current interest for clinical practice.

The GOLD 2019 report recommended using blood eosinophil counts (BEC) as part of a precision medicine strategy to identify the most suitable patients for inhaled corticosteroid (ICS) treatment(3). Recent publications have provided further evidence and insights concerning BEC in COPD. Here, we discuss the role of BEC as a COPD biomarker, focusing on new advances and summarising the associated changes in the GOLD 2022 Report (shown in Table 1).

A brief overview of eosinophil biology

Eosinophils originate from bone marrow stem cells, in response to stimulation by granulocyte-monocyte colony stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5 (4). The subsequent proliferation, activation, tissue infiltration and survival of eosinophils is controlled by type 2 (T2) mediators, such as IL-4, IL-5, IL-13 and eotaxins. Eosinophil degranulation releases major basic proteins, eosinophil cationic protein, eosinophil peroxidase and

eosinophil-derived neurotoxin, which provide host defence against parasitic infection (5). These proteins also promote bacterial and viral clearance, although the extent of these roles in humans, as opposed to animal models, is unclear (4, 5). Eosinophil derived granule proteins can cause tissue injury and remodelling, while eosinophil peroxidase drives changes in the physicochemical properties of mucus that underlie airway mucus plugging (4, 6). There is also evidence that eosinophil subsets exist, with tissue resident cells having a predominantly homeostatic role while inflammatory eosinophils are recruited into the lungs(7). Asthma and systemic hyper-eosinophilic diseases are examples where increased systemic and lung eosinophil numbers, coupled with activation, contribute to disease pathophysiology (4).

BEC as a predictor of inhaled corticosteroid benefit

COPD is a heterogeneous condition, exemplified by the between individual variation in the nature and severity of airway inflammation (3, 8-10). The use of anti-inflammatory treatments therefore requires a selective approach, based on clinical characteristics (phenotyping) and biological information (endotyping) in order to target therapies to subgroups of individuals who are most likely to derive benefit (3, 9, 11). ICS are anti-inflammatory drugs that are used in combination with one or two long-acting bronchodilators (LABD) for the treatment of COPD. Randomized control trials (RCTs) have shown that ICS reduce exacerbation rates, improve quality of life and prevent mortality when targeted to COPD patients with a history of exacerbations (3, 12, 13). Pre-specified and post-hoc analysis of these RCTs have shown that higher BEC, used as a surrogate for lung eosinophil counts(14), at the study start are associated with greater clinical benefits, notably exacerbation prevention, from ICS treatment (3, 14-17). The relationship between BEC and ICS benefits has been described as continuous, as these analysis have demonstrated treatment effects at above (approximately) 100 cells / μL with incremental increases in the magnitude of effect at higher BEC(3, 14). Importantly, there is no

clear evidence that ICS treatment reduces BEC, so BEC retain their predictive value independent of ICS treatment. Accordingly, in 2019 GOLD recommended the use of BEC in clinical practice, in COPD patients with an exacerbation history despite appropriate use of LABD, to identify the most suitable patients for ICS treatment (3). The BEC thresholds < 100 cells / µL and ≥ 300 cells / µL have been proposed, identifying individuals with the lowest and greatest likelihood (respectively) of benefit from ICS treatment when administered on top of LABD. These are estimated, not strict, thresholds. Patients with low BEC appear to be at increased risk of pneumonia(18, 19) (discussed in depth later), while there is also a small increase in pneumonia risk with ICS use in COPD patients(12, 13, 15).

RCTs of inhaled triple therapies have been analysed according to whether patients had 1 or ≥2 exacerbations in the previous year(20, 21). A history of ≥2 exacerbations was associated with more exacerbations during the study compared to 1 previous exacerbation. The benefit of ICS on exacerbation prevention was greater in individuals with more events (i.e. those with a history of ≥2 exacerbations), but there was still a benefit in patients with one previous exacerbation and BEC were able to predict ICS benefits regardless of exacerbation history.

Conclusion: The GOLD 2019 report recommended the use of clinical phenotyping (exacerbation history) combined with endotyping (using BEC as a biomarker) to enable ICS to be used with more precision, selecting individuals with a greater benefit (reduction in exacerbations) versus risk profile (pneumonia occurrence), hence increasing the net benefit potential of ICS (3). RCT results published since 2019 remain supportive of BEC as a predictive biomarker of ICS effects in COPD patients with increased exacerbation risk (15).

Variability of BEC

The intra-class correlation coefficient (ICC) for repeated BEC measurements performed on different days in COPD patients have ranged from 0.64 to 0.89, indicating good to excellent

reproducibility(14). It has been commented that similar ICC values have been reported for cholesterol and glycated Hb which are routinely used biomarkers in clinical practice(3, 14). BEC show diurnal variation in healthy subjects and patients with asthma and COPD, peaking in the early morning, and thought to be related to circadian variation in cortisol secretion(22, 23). The median reduction in BEC at 12.00 compared to 08.00 in COPD patients was reported to be 36%(23).

GOLD has suggested BEC thresholds to help direct ICS treatment(3). Movement across a threshold after repeated measurement is more likely for BEC that are closer to the threshold(24). This is one reason why GOLD states that these are not strict thresholds, and consequently small within or between day variations should not result in a change in clinical management. In support, it has been reported that the predictive ability of BEC, with regard to ICS benefits observed in a triple therapy RCT, were similar regardless of whether the BEC at screening or randomisation was used, or the average of both(25).

BEC in COPD patients versus controls

A study in individuals aged >40 years showed that on average eosinophil counts were higher in COPD patients (n=209) than in controls (n=127) (26). Although there was considerable overlap in the counts between the groups, some COPD patients had higher counts than the controls. A recent cohort study has also shown that BEC are higher in COPD patients (n=326) versus controls (n=399)(27). In contrast, other studies have not shown differences between COPD patients and controls (28), as the CANCOLD study showed a similar distribution of BEC between the non-COPD (n=573) and COPD participants (n=547)(29), while the CHAIN cohort also showed a similar BEC distribution between non-COPD (n=121) and COPD (n=769) participants(30) .

A large general population study in Austria (n=11,042) using multivariate logistic regression showed that a higher BEC (>210 cells/μL; the 75th percentile) was more likely in current smokers (odds ratio (OR) 1.72, 95% confidence interval (CI)1.52–1.96) and COPD (OR 1.56, CI 1.20–2.03), but the range in patients with COPD was not specified (31). In Japanese patients with COPD (n=848), the median (interquartile range) BEC was 170 cells/μL (100–280 cells/μL) with a similar distribution to that in non-Japanese patients with COPD (n=5397), but the counts were not compared to healthy controls(32). Another large general population study, conducted in Japan (approximately 10,000 participants), showed a similar BEC distribution in a healthy population to that seen in the European study, but BEC in patients with COPD were not reported (33).

A meta-analysis reported that the median BEC was higher in COPD patients compared to controls, although the 95% CI overlapped (34). There was high heterogeneity between studies, likely due to different characteristics of populations, particularly controls where co-morbid conditions that increase BEC (e.g. current smoking, allergies and obesity(31)) may not have been fully accounted for.

Conclusion: While the evidence is not consistent across all publications, there are three studies, including a very large population study, showing that, on average, BEC are higher in COPD patients, with a subgroup of COPD patients showing higher counts than seen in controls (26, 27, 31). These observations suggest upregulation of mechanisms that increase eosinophil production from the bone marrow (i.e., the action of GM-CSF, IL-3 and IL-5(4)) or eosinophil

survival in some COPD patients. The lack of consistency across studies may reflect sample size and / or the influence of co-morbidities on BEC (31).

BEC; association with future risk or disease progression

FEV1 decline

In healthy individuals who did not have asthma in the Dunedin Multidisciplinary Health and Development Study (n=971), higher BEC were associated with faster FEV_1 decline between the ages of 21 years and 38 years (35). The relationship persisted after adjusting for smoking. Another study retrospectively analysed private healthcare screening records (n>359,000) of younger adults without a history of asthma or airflow obstruction (mean age 36 yrs; median follow up 5.6 years) (36). The development of airflow obstruction was associated with higher BEC at baseline, which was also observed in the smoker subgroup. Additionally, there was an association between higher BEC and the development of physician diagnosed COPD plus spirometric confirmation of airflow obstruction, defined as FEV1/FVC <0.7 and FEV1 <80%. A limitation of this study is that post-bronchodilator spirometry was not performed. In the CANCOLD study (n=1120; mean age 65 years), using a multivariate regression model which accounted for baseline factors including FEV_1, exacerbation history and ICS use, individuals with BEC ≥300 cells / µL had more rapid FEV_1 decline than those with <150 cells / µL (mean difference 34.3 ml / year) (29). The same pattern was apparent in the COPD subgroup (n=466). Overall, these data from large cohort studies show that higher BEC are associated with more rapid FEV_1 decline both in younger adults without airflow obstruction and patients with COPD and, in some individuals, this leads to the development of COPD.

Data from UK electronic medical records from COPD patients with FEV_1 50 – 90% predicted (n=12,178) showed greater FEV_1 decline in patients with more exacerbations over >3 years follow up (37). There was an interaction between exacerbation frequency and BEC, with a more rapid loss of lung function in patients with ≥ 2 exacerbations / year and BEC ≥350 cells/μL, which was reduced by ICS use. However, in patients without exacerbations, the rate of FEV_1 decline was approximately 10ml/year less in patients with BEC≥350 cells/μL compared to those with lower BEC. This study confirms the importance of exacerbations as a determinant of FEV_1 decline (38), and demonstrates complex relationships between BEC and FEV_1 decline which are dependent on both exacerbation frequency and ICS use. An analysis of >26,000 COPD patients from the same database source showed that new ICS use versus no ICS use was associated with reduced FEV1 decline in subjects with BEC >150 /uL(39), but exacerbations were not analysed. A post-hoc analysis of the ISOLDE study also showed that in patients with BEC ≥2%, FEV1 decline was reduced by ICS treatment (40). The Hokkaido COPD cohort, with a smaller sample size (n=279) and low ICS use (<15%), reported that mean BEC were lower in the rapid decliners compared to the slow decliners or sustainers (41). Again, exacerbations were not reported in this study.

Conclusion: In younger individuals without COPD, there is evidence of an association between higher BEC and both faster FEV_1 decline and the development of airflow obstruction (35, 36). These observations mechanistically implicate eosinophils and / or other associated components of T2 inflammation in the development of COPD, at least in some patients. In patients with confirmed COPD, the association between higher BEC and FEV_1 decline is complex and findings from cohort studies have been inconsistent, being influenced by disease heterogeneity including prior exacerbation frequency and use of ICS(37-39). These complexities mean that using BEC alone in COPD patients to predict lung function decline is a simplistic approach

that is unlikely to be of clinical utility. Nevertheless, FEV_1 decline appears to be greater in individuals with more exacerbations(37, 38), and ICS may reduce the rate of decline in individuals who have greater exacerbation risk plus higher BEC(37). These observational data, following COPD patients for ≥ 3 years, support the results of multiple RCTs conducted over 1 year; both demonstrate a relationship between BEC and ICS benefits in COPD patients with a history of exacerbations (14-16, 42).

Exacerbation risk

Some cohort studies have reported an association between BEC and exacerbation risk in patients with COPD, while others have found no relationship (30, 43-49). These contradictory findings generally reflect differences in baseline exacerbation history (which is the strongest predictor of exacerbation risk(50)) and ICS use, which RCTs have shown weaken the relationship between exacerbation risk and BEC(14, 16, 17, 42). Cohort studies have generally not adjusted for these factors. Analysis of two cohorts with prospective follow up data (n=1113 and n=1895) reported that BEC ≥ 300 cells/μL were associated with increased exacerbation frequency; this association was driven by the subgroup of individuals with ≥2 exacerbations in the year before study start, with incident risk ratios of 1.96 and 1.4 for individuals with BEC ≥ 300 cells/μL versus < 300 cells/μL in this subgroup (51). The relationships between BEC and exacerbation risk remained after adjusting for ICS use.

Analyses of RCTs investigating ICS containing combination treatments in COPD patients with a history of exacerbations have shown that higher baseline BEC are associated with a higher rate of exacerbations over 12-months in patients not treated with ICS (15-17, 42). In contrast, a pooled analysis of 11 RCTs investigating LABD, involving patents with and without a history

of exacerbations, found no relationship between BEC and exacerbation rates in patients not taking ICS (who also had lower exacerbation rates) (52). Exacerbation rates in patients taking ICS with were slightly higher (9%) in patients with BEC >300 cells / μL compared to those with counts ≤ 150 cells / μL (52).

Conclusion; Exacerbation history remains the best predictor of future exacerbation risk (50, 51). The potential usefulness of BEC as a predictor of future exacerbation risk is restricted to patients with a history of exacerbations, and BEC have been consistently associated with exacerbation risk in the non-ICS treatment arms of RCTs involving this clinical phenotype(15-17, 42). However, in cohort studies this relationship is less consistent, being modified by ICS use and influenced by the inclusion of low exacerbation risk individuals(30, 43-49, 51). Consequently, BEC are not a useful stand-alone biomarker of exacerbation risk in clinical practice.

Mortality

In the CHAIN and BODE cohorts, all-cause mortality over 20 years was lower in COPD patients with high BEC compared with those with values <300 cells/μL (15.8% versus 33.7%; p=0.026) after adjusting for age, sex, body mass index (BMI), lung function and Charlson index(30). Over half the patients were taking ICS but the analysis was not adjusted for this. In a French cohort, there was no relationship between BEC and 3-year survival, with over 85% of patients taking ICS (46). The ETHOS RCT, conducted in patients at high exacerbation risk, showed that the benefit of ICS (as part of triple combination treatment) on mortality was greater at higher BEC(53). This mortality benefit due to ICS was accompanied by exacerbation prevention at higher BEC(15).

Conclusions. BEC used alone are not a reliable predictor of mortality, as the risk is modified by ICS use. However, in the high exacerbation risk phenotype, RCT evidence supports higher BEC as a biomarker of increased mortality risk in individuals not using ICS(53).

BEC and T2 inflammation

The consistent relationship between BEC and ICS effects on exacerbation rates in COPD RCTs indicates that BEC reflect differential profiles of pulmonary inflammation within a heterogeneous condition(14, 16, 17, 54). Significant associations have been reported between BEC and pulmonary eosinophil counts (from sputum or lung tissue), with the strength of the relationship ranging from 0.18 to 0.7(49, 55-60). While these studies confirm that BEC reflect pulmonary eosinophil numbers, the association has been weak in some studies. The reasons for a weak association include the inherent variability of lung sampling (e.g. between day variation in sputum eosinophil counts(10)) and sometimes a lack of methodological precision in eosinophil counts (e.g. using only one significant figure for BEC) (49). Furthermore, the distribution of eosinophils in lung tissue is patchy (61), which may explain the lack of association between blood and tissue eosinophils in one study (62), in contrast to the positive relationship reported in other studies (55, 63, 64).

Studies using bronchoscopy, induced sputum and lung surgical tissue samples have demonstrated a T2 inflammation profile in patients with higher BEC. Kolsum et al obtained bronchoscopy and sputum samples from 41 COPD patients with higher (>250 cells / μL) or lower (<150 cells / μL) BEC(64), and no previous asthma diagnosis or skin testing evidence of atopy. The higher BEC group had increased eosinophil counts in sputum, bronchoalveolar

lavage and bronchial mucosal tissue, plus increased protein levels of mediators involved in eosinophil activation and chemotaxis (IL-5 and C-C motif chemokine ligand (CCL)24). The higher BEC group also exhibited increased reticular basement membrane thickening. A subsequent analysis of this study focused on gene expression of six T2 markers increased in patients with asthma (65). Four genes, namely chloride channel accessory 1 (CLCA1), CCL26, IL-13 and cystatin SN (CST1), had increased expression in both sputum cells and bronchial brushings in the higher BEC COPD group, with these results validated in sputum samples from a different cohort (n=33). Bronchial epithelial brushings from the Emphysema versus Airway disease (EvA) study (n=283) also showed differential gene expression in bronchial brushings from COPD patients with higher BEC, including CLCA1, CCL26 and CST1 (66). An asthma cohort, analysed by the authors for comparison, showed far more differentially expressed genes associated with BEC, suggesting a restricted T2 signature in COPD compared to asthma. Sputum cells obtained at the baseline visit of a RCT showed a differential gene expression profile in samples with eosinophil counts ≥3% versus <3%, including known T2 markers(67). Jogdand et al reported that eosinophil numbers in the conducting airways and lung parenchyma were associated with more severe COPD and tissue basophil counts(61).

Conclusion: Higher BEC in COPD patients are associated with both increased numbers of eosinophils and levels of markers of T2 inflammation in the lungs(64-66). This differential inflammation profile could explain the association between BEC and ICS responses, as T2 inflammation can respond well to corticosteroid treatment(68, 69). RCTs of biological treatments targeting IL-5 or the IL-5 receptor, thereby reducing BEC, have failed to demonstrate efficacy on exacerbation rates (the primary endpoint) in COPD populations enriched for increased exacerbation risk and higher BEC(70, 71). A contributor to these negative outcomes is that higher BEC appear to mark a wider T2 inflammation profile(61, 64-

66), and selective depletion of eosinophil numbers will not modulate other T2 components. BEC could be used as a biomarker to identify COPD patients suitable for clinical trials of novel therapeutics targeting T2 pathways(14).

BEC and microbiome

Sputum samples obtained during the stable state from 510 patients with COPD were analysed for cell counts and microbiome characteristics (by 16S rRNA sequencing) (10). Cross sectional analysis showed that neutrophilic inflammation was associated with heterogeneous microbiome patterns, including a subset with a haemophilus dominant microbiome. In contrast, eosinophilic inflammation was associated with several non-dominant genera but not haemophilus. Longitudinal analysis showed that eosinophilic samples that became non-eosinophilic over time also did not display a haemophilus dominant microbiome. Similarly, studies in COPD patients using quantitative polymerase chain reaction quantification of bacterial species have shown that haemophilus influenzae presence is associated with higher sputum neutrophil counts and lower sputum eosinophil counts (72-74). Interestingly, bronchoscopy samples from COPD patients with lower (versus higher) BEC showed decreased immunoglobulin subtype levels and reduced opsonisation of non-typeable haemophilus influenzae; this provides a possible explanation for higher sputum haemophilus influenzae levels in patients with lower eosinophil counts (75).

Dicker et al showed that higher BEC were associated with lower proteobacteria abundance (which includes the haemophilus genera), and greater abundance of the firmicutes phyla in a cohort of 296 COPD patients(76). Furthermore, there was an increase in haemophilus abundance for patients with BEC ≤100 cells / μL compared to > 100 cells / μL. Subgroup

analysis showed that the profile of inflammatory proteins in sputum was different in samples with proteobacteria dominance, favouring mediators of neutrophilic inflammation, when compared to firmicutes dominant samples. Overall, these cohort studies have highlighted that lower eosinophil counts (in sputum and blood) are associated with a different microbiome profile, characterised by increased proteobacteria.

Martinez-Garcia et al reported that BEC<100 cells / μL were associated with increased incidence of chronic bacterial infection (CBI) and pneumonia episodes in 201 COPD patients (median follow up 7 years) (19). A multivariate regression model showed that age, FEV_1, CBI, and BEC<100 cells/μl were all independently associated with greater pneumonia risk. Higher BEC thresholds (<150 cells /μl and <300 cells /μl) were not significantly associated with increased pneumonia risk. ICS use was not associated with pneumonia risk in the overall population, although ICS further increased the risk of pneumonia (hazard ratio [HR] 2.9) in those with CBI and <100 eosinophils/μl. A pooled analysis of 10 randomised control trials of ICS containing combination treatments in COPD patients showed that the risk of pneumonia was higher in patients at baseline BEC <2% versus ≥2%; HR 1·31 (95% CI 1·06–1·62)(18). A potential explanation for these pneumonia findings comes from a small COPD RCT (n=60) which showed that ICS containing combination treatment over one year increased sputum bacterial load, in contrast to no change without ICS; this increase was present in those with lower BEC only(77).

Conclusion: Recent studies have consistently shown that lower sputum and blood eosinophil counts are associated with an increased presence of proteobacteria phylum/haemophilus genera(10, 72-74, 76). Lower BEC also appear to be associated with an increased risk of

recurrent bacterial infections and pneumonia, and these risks seem to be increased by ICS use in patients with lower BEC(19, 77, 78). Overall, these findings regarding microbiome and pneumonia risk provide additional reasons not to use ICS in COPD patients with lower BEC.

Summary and conclusions

The GOLD 2019 report first introduced BEC as a biomarker to help make pharmacological treatment decisions, concerning ICS use, in COPD patients with a history of exacerbations (3). The GOLD 2022 report now adds various additional evidence concerning BEC (key points shown in Table 1), including the connections between BEC, T2 inflammation(61, 64-66) and lung microbiome(10, 72-74, 76) which identify COPD subgroups with increased ICS response (higher BEC) or increased risk of bacterial infection (lower BEC); summarised in Figure 1. This evidence supports an integrated evaluation of clinical history (notably exacerbation history), BEC and sputum microbiology in order to provide a personalised management approach with regard to when ICS should be used on top of LABD and the management of airway infection.

Accumulating evidence indicates an association between lower BEC and the incidence of both CBI and pneumonia events (18, 19), coupled with a differential microbiome profile (greater abundance of haemophilus influenza)(10, 72-74, 76). Based on this evidence, lower BEC (<100 cells/µl) could be used as a biomarker, in combination with clinical history, to help identify patients who require careful monitoring for bacterial colonisation. Furthermore, in these individuals, the absence of T2 inflammation coupled with the increased risk of bacterial infection, argues against the use of ICS. The importance of bacterial colonization was demonstrated in an observational COPD cohort where exacerbation risk was greatest in individuals with haemophilus influenza colonization and exposure to rhinovirus infection (79),

indicating an interplay between pathogens leading to worse clinical outcomes. Further studies should elucidate the mechanisms responsible for the association between T2 inflammation and the microbiome, as this may help identify novel therapeutic interventions.

COPD patients with higher BEC have more T2 inflammation (61, 64-66), which can explain a differential response to ICS. It is important to note that RCTs have demonstrated a benefit for ICS (as part of combination treatments) only in COPD patients with an exacerbation history in the previous year (3, 14). There is currently no evidence supporting ICS intervention in COPD patients with higher BEC but without a history of exacerbations, although this is an evidence gap worth considering. Furthermore, the association between higher BEC and FEV1 decline in younger adults (36) provides a rationale to study the effects of ICS on disease progression / lung function decline in younger COPD patients with higher BEC (80).

BEC are not a stand-alone biomarker of future risk (of FEV1 decline, exacerbations, and mortality) in patients with COPD, due to the complex relationship with exacerbation risk and confounding due to ICS use(37). However, in younger individuals, higher BEC may serve as a biomarker to help identify those at increased risk of developing COPD (36), and further evidence is needed to evaluate the utility of BEC in this context.

RCTs have shown that, in COPD patients with a history of exacerbations, higher BEC identify a subgroup with increased exacerbation risk that can be therapeutically modified by ICS(15-17). On the other hand, we also point out a subgroup with lower BEC (<100 cells/µl) with a different microbiome profile and increased risk of chronic bacterial infection(19, 76). These findings might suggest that BEC predict a “U shaped” future risk curve, albeit one that is influenced by other factors including exacerbation history and ICS use.

In conclusion, the GOLD 2022 report incorporates new evidence regarding BEC, notably the relationships with T2 inflammation(64-66) and the microbiome(10, 72-74, 76). These findings further our understanding of COPD subtypes, facilitating precision medicine strategies based on clinical phenotyping combined with endotyping(9, 11).

ACKNOWLEDGEMENTS

Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). We acknowledge and thank the members of the GOLD science committee for contributing to informative discussions on this topic. We thank Andrew Higham for assistance with the figure artwork.

Figure legends

Figure 1: The relationships between blood eosinophil counts (BEC) and Type-2 (T2) inflammation, microbiome, bacterial infection / pneumonia episodes and inhaled corticosteroid (ICS) response (exacerbation prevention).

REFERENCES

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163: 1256-1276.
2. Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agusti A, all p, current members of the Science C, the Board of Directors of G. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. *Eur Respir J* 2017; 50.
3. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, Lopez Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J* 2019; 53.
4. Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, Wardlaw AJ, Dougan SK, Berdnikovs S, Schleich F, Matucci A, Chanez P, Prazma CM, Howarth P, Weller PF, Merkel PA. Eosinophils in Health and Disease: A State-of-the-Art Review. *Mayo Clin Proc* 2021; 96: 2694-2707.
5. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. *J Biol Chem* 2014; 289: 17406-17415.

6. Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di Maio S, Hoffman EA, Castro M, Fain SB, Jarjour NN, Israel E, Levy BD, Erzurum SC, Wenzel SE, Meyers DA, Bleecker ER, Phillips BR, Mauger DT, Gordon ED, Woodruff PG, Peters MC, Fahy JV, National Heart L, Blood Institute Severe Asthma Research P. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. *J Clin Invest* 2018; 128: 997-1009.
7. Marichal T, Mesnil C, Bureau F. Homeostatic Eosinophils: Characteristics and Functions. *Front Med (Lausanne)* 2017; 4: 101.
8. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350: 2645-2653.
9. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. *Lancet* 2015; 385: 1789-1798.
10. Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W, Brown JR, Tal-Singer R, Barer MR, Bafadhel M, Donaldson GC, Wedzicha JA, Singh D, Wilkinson TMA, Miller BE, Brightling CE. Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. *Am J Respir Crit Care Med* 2021; 203: 1488-1502.
11. Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2016; 194: 541-549.
12. Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A. Inhaled corticosteroids in COPD: friend or foe? *Eur Respir J* 2018; 52.
13. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, Investigators I. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med* 2018; 378: 1671-1680.
14. Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, Pasquale CB, Merrill DD, Metzdorf N, Petruzzelli S, Tal-Singer R, Compton C, Rennard S, Martin UJ. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2020; 202: 660-671.
15. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P, Investigators E. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med* 2020; 383: 35-48.
16. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med* 2019; 7: 745-756.
17. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018; 6: 117-126.
18. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. *Lancet Respir Med* 2016; 4: 731-741.
19. Martinez-Garcia MA, Faner R, Oscullo G, de la Rosa D, Soler-Cataluna JJ, Ballester M, Agusti A. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in

Chronic Obstructive Pulmonary Disease. A Network Analysis. *Am J Respir Crit Care Med* 2020; 201: 1078-1085.

20. Halpin DMG, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, Singh D, Wise R, Criner GJ. The effect of exacerbation history on outcomes in the IMPACT trial. *Eur Respir J* 2020; 55.
21. Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. *Eur Respir J* 2019; 53.
22. Durrington HJ, Gioan-Tavernier GO, Maidstone RJ, Krakowiak K, Loudon ASI, Blaikley JF, Fowler SJ, Singh D, Simpson A, Ray DW. Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. *Am J Respir Crit Care Med* 2018; 198: 1578-1581.
23. Van Rossem I, Hanon S, Verbanck S, Vanderhelst E. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: Adding Within-Day Variability to the Equation. *Am J Respir Crit Care Med* 2022; 205: 727-729.
24. Long GH, Southworth T, Kolsum U, Donaldson GC, Wedzicha JA, Brightling CE, Singh D. The stability of blood Eosinophils in chronic obstructive pulmonary disease. *Respir Res* 2020; 21: 15.
25. Bafadhel M, Barnes N, Bourke S, Compton C, Criner GJ, Dransfield M, Halpin D, Han MK, Hartley B, Jones C, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez F, Van der Valk RJP, Wise R, Singh D. Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? *Eur Respir J* 2019; 52.
26. Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. *Eur Respir J* 2019; 54.
27. Miravitlles M, Soler-Cataluna JJ, Soriano JB, Garcia-Rio F, de Lucas P, Alfageme I, Casanova C, Rodriguez Gonzalez-Moro JM, Sanchez-Herrero MG, Ancochea J, Cosio BG. Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study. *Respir Res* 2022; 23: 49.
28. Tine M, Biondini D, Semenzato U, Bazzan E, Cosio MG, Saetta M, Turato G. Reassessing the Role of Eosinophils as a Biomarker in Chronic Obstructive Pulmonary Disease. *J Clin Med* 2019; 8.
29. Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, Kirby M, Hogg JC, Sin DD, Can CCRG, authors would also like to thank the m, women who participated in the s, individuals in the Can CCRGnlaa. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. *Eur Respir J* 2021; 57.
30. Casanova C, Celli BR, de-Torres JP, Martinez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G, Calle-Rubio M, Solanes I, Aguero R, Feu-Collado N, Alfageme I, De Diego A, Romero A, Balcells E, Llunell A, Galdiz JB, Marin M, Moreno A, Cabrera C, Golpe R, Lacarcel C, Soriano JB, Lopez-Campos JL, Soler-Cataluna JJ, Marin JM. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. *Eur Respir J* 2017; 50.
31. Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, Urban MH, Agusti A, Studnicka M, Wouters EFM, Breyer-Kohansal R. Blood eosinophil count in the general population: typical values and potential confounders. *Eur Respir J* 2020; 55.
32. Barnes N, Ishii T, Hizawa N, Midwinter D, James M, Hilton E, Jones PW. The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 433-440.
33. Sunadome H, Sato S, Matsumoto H, Murase K, Kawaguchi T, Tabara Y, Chin K, Matsuda F, Hirai T. Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study. *Eur Respir J* 2021; 57.

34. Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. *Eur Respir J* 2022; 59.
35. Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. *Eur Respir J* 2018; 51.
36. Park HY, Chang Y, Kang D, Hong YS, Zhao D, Ahn J, Shin SH, Singh D, Guallar E, Cho J, Ryu S. Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study. *Eur Respir J* 2021; 58.
37. Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks JW, Sadatsafavi M, Sin DD, Carter V, Price DB. Association between COPD exacerbations and lung function decline during maintenance therapy. *Thorax* 2020; 75: 744-753.
38. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI, Investigators E. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011; 365: 1184-1192.
39. Whittaker HR, Mullerova H, Jarvis D, Barnes NC, Jones PW, Compton CH, Kiddle SJ, Quint JK. Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 1063-1073.
40. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. *Eur Respir J* 2016; 47: 1374-1382.
41. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine* 2012; 185: 44-52.
42. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med* 2015; 3: 435-442.
43. DiSantostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. *Respir Med* 2016; 112: 88-96.
44. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. *Am J Respir Crit Care Med* 2016; 193: 965-974.
45. Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agusti A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB. Blood eosinophil count and exacerbation risk in patients with COPD. *Eur Respir J* 2017; 50.
46. Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, Nesme-Meyer P, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N, Burgel PR. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1819-1824.
47. Mullerova H, Hahn B, Simard EP, Mu G, Hatipoglu U. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 683-692.
48. Miravitlles M, Monteagudo M, Solntseva I, Alcazar B. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. *Arch Bronconeumol (Engl Ed)* 2021; 57: 13-20.
49. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, Barr RG, Carretta EE, Couper DJ, Cooper CB, Hoffman EA, Kanner RE, Kleerup E, O'Neal WK, Paine R, 3rd, Peters SP, Alexis NE, Woodruff PG, Han MK, Meyers DA, Bleecker ER,

investigators S. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med* 2017; 5: 956-967.

50. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of CLtIPSEI. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363: 1128-1138.
51. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP, Copdgene, Investigators E. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2018; 141: 2037-2047 e2010.
52. Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. *Respir Res* 2020; 21: 240.
53. Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, Rossman K, St Rose E, Trivedi R, Ballal S, Darken P, Aurivillius M, Reisner C, Dorinsky P. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. *Am J Respir Crit Care Med* 2021; 203: 553-564.
54. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2015; 192: 523-525.
55. Higham A, Singh D. Stability of eosinophilic inflammation in COPD bronchial biopsies. *Eur Respir J* 2020; 56.
56. Singh D, Watz H, Beeh KM, Kornmann O, Leaker B, Colgan B, Lucci G, Emirova A, Nandeuil MA, Santoro D, Balzano D, Govoni M. COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. *Eur Respir J* 2020; 56.
57. Schleich F, Corhay JL, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. *Eur Respir J* 2016; 47: 1562-1564.
58. Pignatti P, Visca D, Cherubino F, Zampogna E, Lucini E, Saderi L, Sotgiu G, Spanevello A. Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients. *Respir Res* 2019; 20: 145.
59. Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, Gibson PG. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 1495-1504.
60. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, investigators E. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J* 2014; 44: 1697-1700.
61. Jogdand P, Siddhuraj P, Mori M, Sanden C, Jonsson J, Walls AF, Kearley J, Humbles AA, Kolbeck R, Bjermer L, Newbold P, Erjefalt JS. Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. *Eur Respir J* 2020; 55.
62. Turato G, Semenzato U, Bazzan E, Biondini D, Tine M, Torrecilla N, Forner M, Marin JM, Cosio MG, Saetta M. Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2018; 197: 1216-1219.
63. Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. *Respirology* 2015; 20: 667-670.
64. Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P, Newbold P, Singh D. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol* 2017; 140: 1181-1184 e1187.

65. Higham A, Beech A, Wolosianka S, Jackson N, Long G, Kolsum U, Southworth T, Pham TH, Sridhar S, McCrae C, Newbold P, Singh D. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. *Allergy* 2021; 76: 1861-1864.
66. George L, Taylor AR, Esteve-Codina A, Soler Artigas M, Thun GA, Bates S, Pavlidis S, Wagers S, Boland A, Prasse A, Boschetto P, Parr DG, Nowinski A, Barta I, Hohlfeld J, Greulich T, van den Berge M, Hiemstra PS, Timens W, Hinks T, Wenzel S, Siddiqui S, Richardson M, Venge P, Heath S, Gut I, Tobin MD, Edwards L, Riley JH, Djukanovic R, Auffray C, De-Meulder B, Erik-Dahlen S, Adcock IM, Chung KF, Ziegler-Heitbrock L, Sterk PJ, Singh D, Brightling CE, U B, the Ev Ast. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. *Allergy* 2020; 75: 370-380.
67. Singh D, Bassi M, Balzano D, Lucci G, Emirova A, Anna Nandeuil M, Jellema G, Afolabi EK, Leaker B, Kornmann O, Michael Beeh K, Watz H, Govoni M. COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum. *J Cell Mol Med* 2021; 25: 905-918.
68. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc Natl Acad Sci U S A* 2007; 104: 15858-15863.
69. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med* 2009; 180: 388-395.
70. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramirez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ, Investigators GS, Investigators TS. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med* 2019; 381: 1023-1034.
71. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. *N Engl J Med* 2017; 377: 1613-1629.
72. Beech A, Lea S, Li J, Jackson N, Mulvanny A, Singh D. Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes. *Biomedicines* 2021; 9.
73. Beech AS, Lea S, Kolsum U, Wang Z, Miller BE, Donaldson GC, Wedzicha JA, Brightling CE, Singh D. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. *Respir Res* 2020; 21: 289.
74. Diver S, Richardson M, Haldar K, Ghebre MA, Ramsheh MY, Bafadhel M, Desai D, Cohen ES, Newbold P, Rapley L, Rugman P, Pavord ID, May RD, Barer M, Brightling CE. Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus-predominant subgroup. *Allergy* 2020; 75: 808-817.
75. Southworth T, Higham A, Kolsum U, Li J, Scott T, Dungwa J, Sridhar S, Pham TH, Newbold P, Singh D. The relationship between airway immunoglobulin activity and eosinophils in COPD. *J Cell Mol Med* 2021; 25: 2203-2212.
76. Dicker AJ, Huang JTJ, Lonergan M, Keir HR, Fong CJ, Tan B, Cassidy AJ, Finch S, Mullerova H, Miller BE, Tal-Singer R, Chalmers JD. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2021; 147: 158-167.
77. Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, Forini G, Gnesini G, Marku B, Barnes N, Rizzi A, Curradi G, Caramori G, Morelli P, Papi A. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. *Eur Respir J* 2017; 50.
78. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. *Lancet Respir Med* 2016; 4: 731-741.

79. Wilkinson TMA, Aris E, Bourne S, Clarke SC, Peeters M, Pascal TG, Schoonbroodt S, Tuck AC, Kim V, Ostridge K, Staples KJ, Williams N, Williams A, Wootton S, Devaster JM, Group AS. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. *Thorax* 2017; 72: 919-927.
80. Martinez FJ, Agusti A, Celli BR, Han MK, Allinson J, Bhatt SP, Calverley P, Chotirmall SH, Chowdhury B, Darken P, Da Silva CA, Donaldson G, Dorinsky P, Dransfield M, Faner R, Halpin DM, Jones P, Krishnan JA, Locantore N, Martinez FD, Mullerova H, Price D, Rabe KF, Reisner C, Singh D, Vestbo J, Vogelmeier CF, Wise RA, Tal-Singer R, Wedzicha JA. Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. *Am J Respir Crit Care Med* 2021.

Table 1. GOLD 2022 Report: Key evidence and recommendations for blood eosinophil counts in COPD

Prediction of ICS benefits • The use of BEC to predict ICS effects should be combined with exacerbation risk (using exacerbation history) • The relationship between BEC and ICS effects is continuous; no / small effects are observed at lower BEC, with increasing effects at higher BEC • < 100 cells/µL and ≥ 300 cells/µL are estimates, not precise cut-off values, to identify individuals with the lowest and greatest (respectively) likelihood of ICS benefit
Type-2 inflammation • Higher BEC are associated with increased lung eosinophil numbers and higher levels of type-2 inflammation markers in the airways • The differences in type-2 inflammation can explain the differential ICS response according to BEC
COPD versus controls • A subset of COPD patients have BEC above those found in controls
Microbiome • Lower BEC are associated with greater presence of proteobacteria, notably haemophilus, and increased bacterial infections and pneumonia
Future risk (of exacerbations / disease progression) • In younger individuals without COPD, higher BEC are associated with increased risk of FEV_1 decline and the development of COPD • BEC cannot be used as a standalone biomarker of future risk without considering exacerbation risk and ICS use

Abbreviations: BEC = blood eosinophil count. ICS= inhaled corticosteroid



*<100 cells/µL
**In COPD patients with increased exacerbation risk